Taysha Gene Therapies Stock

Taysha Gene Therapies Dividend 2024

Taysha Gene Therapies Dividend

0 USD

Taysha Gene Therapies Dividend yield

Ticker

TSHA

ISIN

US8776191061

WKN

A2QCJL

How much dividend does Taysha Gene Therapies 2024 pay?

According to the latest status from October 2024, Taysha Gene Therapies paid a total of 0 USD per share in dividends within the last 12 months. With the current Taysha Gene Therapies price of 2.02 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Taysha Gene Therapies Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Taysha Gene Therapies Dividend Safe?

Taysha Gene Therapies has been increasing the dividend for 0 years.

Over the past 5 years, Taysha Gene Therapies has increased it by an annual 0 %.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Taysha Gene Therapies's Dividend Distributions

Taysha Gene Therapies’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Taysha Gene Therapies's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Taysha Gene Therapies's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Taysha Gene Therapies’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Taysha Gene Therapies Aktienanalyse

What does Taysha Gene Therapies do?

Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas, focused on discovering and developing gene therapies for severe neurological disorders. The company was founded in 2019 by leading pharmaceutical entrepreneur RA Capital Management and gene therapy developer Dr. Steven Gray. Taysha Gene Therapies' business model is based on the belief that gene therapy has the potential to revolutionize medicine. The company is dedicated to developing gene therapies that can be used to treat rare genetic diseases, particularly pediatric diseases that have had limited or no treatment options. Their goal is to create innovative therapeutic approaches to improve the lives of affected patients and their families. To achieve this, the company conducts extensive research and development work, addressing the challenging questions and challenges in their field. The biggest hurdle in gene therapy development is the need to tailor treatments to the specific defects of individual patients, requiring personalized therapy. Taysha Gene Therapies addresses this issue through the use of AAV gene therapies, which provide a versatile tool and allow the company to diversify. Currently, the company has four different divisions focused on developing gene therapies for rare diseases. Their first priority is TSHA-101, a gene therapy targeting Angelman syndrome, a genetic disorder that occurs in babies and toddlers and can cause epileptic seizures, developmental delays, sleep disorders, and speech problems. Taysha Gene Therapies is also working on therapies for Tay-Sachs and GM1 gangliosidosis, which are also rare and severe diseases. Additionally, the company is developing therapies for Rett syndrome. Taysha Gene Therapies aims to make global progress in the field of neuropsychiatric and neurological disorders by setting new standards and creating innovative concepts. The company collaborates with leading geneticists, scientists, and neurologists to incorporate the latest technologies in gene therapy development. They have the potential to elevate the treatment of rare genetic diseases that have had limited or no treatment options. In their efforts to improve patient care, Taysha Gene Therapies has formed partnerships with other companies and institutions. In March 2020, they established partnerships with UT Southwestern, RCPD, and AveXis to facilitate the exchange of data and expertise on selected treatment options. This collaboration aims to accelerate progress in gene therapy and develop new therapies and technologies that enhance patient treatment and quality of life. Overall, Taysha Gene Therapies is engaged in exciting and innovative work focused on implementing gene therapies for rare genetic diseases. With their innovative approaches to therapy concept development, partnerships with leading institutions, and excellent collaboration with other companies, they aim to make a significant contribution to improving healthcare. Output: Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas. It focuses on discovering and developing gene therapies for severe neurological disorders, particularly rare genetic diseases in children. The company aims to improve the lives of patients and their families through innovative therapies. It collaborates with experts and uses cutting-edge technologies. Taysha Gene Therapies also partners with other organizations to accelerate progress and improve patient care. Its mission is to revolutionize medicine and contribute to healthcare improvement. Taysha Gene Therapies is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Taysha Gene Therapies stock

How much dividend does Taysha Gene Therapies pay?

Over the past 12 months, Taysha Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Taysha Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Taysha Gene Therapies?

The current dividend yield of Taysha Gene Therapies is .

When does Taysha Gene Therapies pay dividends?

Taysha Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taysha Gene Therapies?

Taysha Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Taysha Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taysha Gene Therapies located?

Taysha Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taysha Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taysha Gene Therapies from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Taysha Gene Therapies pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Taysha Gene Therapies in the year 2023?

In the year 2023, Taysha Gene Therapies distributed 0 USD as dividends.

In which currency does Taysha Gene Therapies pay out the dividend?

The dividends of Taysha Gene Therapies are distributed in USD.

Andere Kennzahlen von Taysha Gene Therapies

Our stock analysis for Taysha Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taysha Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.